Xencor, Inc. (NASDAQ:XNCR - Get Free Report) shares fell 6.1% during trading on Monday . The company traded as low as $10.60 and last traded at $10.58. 79,704 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 619,308 shares. The stock had previously closed at $11.26.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the stock. StockNews.com cut shares of Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Wedbush restated an "outperform" rating and issued a $31.00 price objective on shares of Xencor in a research note on Wednesday, April 30th. Wells Fargo & Company decreased their target price on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Finally, William Blair assumed coverage on Xencor in a report on Monday, April 21st. They set an "outperform" rating for the company. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $32.86.
Read Our Latest Stock Report on Xencor
Xencor Price Performance
The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $583.45 million, a P/E ratio of -2.56 and a beta of 0.99. The company has a 50 day moving average of $10.96 and a 200-day moving average of $17.83.
Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $32.73 million during the quarter, compared to analyst estimates of $23.44 million. The company's revenue was up 104.6% on a year-over-year basis. During the same quarter last year, the company posted ($1.11) earnings per share. On average, sell-side analysts predict that Xencor, Inc. will post -3.68 EPS for the current year.
Insider Activity at Xencor
In other news, EVP Nancy Valente sold 4,616 shares of the company's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total transaction of $50,914.48. Following the completion of the sale, the executive vice president now directly owns 49,169 shares in the company, valued at approximately $542,334.07. This represents a 8.58 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 5.23% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of XNCR. Vanguard Group Inc. increased its holdings in Xencor by 5.5% in the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company's stock valued at $184,239,000 after buying an additional 418,040 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Xencor by 2.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,036,412 shares of the biopharmaceutical company's stock valued at $92,758,000 after acquiring an additional 107,350 shares during the last quarter. TCG Crossover Management LLC increased its stake in Xencor by 1.0% in the fourth quarter. TCG Crossover Management LLC now owns 2,452,138 shares of the biopharmaceutical company's stock valued at $56,350,000 after acquiring an additional 25,000 shares during the last quarter. RTW Investments LP raised its position in Xencor by 317.9% during the fourth quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company's stock valued at $55,218,000 after purchasing an additional 1,827,883 shares in the last quarter. Finally, BVF Inc. IL lifted its stake in Xencor by 169.3% during the fourth quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company's stock worth $52,596,000 after purchasing an additional 1,438,760 shares during the last quarter.
About Xencor
(
Get Free Report)
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Featured Stories
Before you consider Xencor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.
While Xencor currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
